EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE


LinkedIn facebook twitter youtube

News

1 2 3 24

  

The phase 3 MAIA study evaluated D-Rd versus Rd in 737 patients who were ineligible for high-dose chemotherapy and autologous stem cell transplantation. The primary analysis of MAIA demonstrated a 44% reduction in the risk of disease progression or death after treatment with D-Rd compared with Rd alone. At a median follow-up of almost 5 years (56.2 months), we now report the pre-specified interim overall survival analysis of MAIA according to the results presented at the European of Hematology Association (EHA) annual meeting, held virtually from from 9 to 17 June. Continue reading

 

The European Hematology Association’s annual congress (EHA 2021) is one of the most important haematology congresses in Europe and it is taking place from 9 to 17 June. 

 

Results from Part 1 of the CASSIOPEIA phase-3 study compared the addition of daratumumab to bortezomib, thalidomide, and dexamethasone (D-VTd) induction/consolidation with VTd alone in transplant-eligible patients with newly diagnosed myeloma has been presented. Continue reading

  

Today, Myeloma Patients Europe (MPE) and KU Leuven present findings from a study at the European Haematology Association 2021 congress (EHA 2021), which aimed to understand which characteristics of treatment myeloma patients find most important. This study illustrates that patients focus not only on treatment efficacy, but also value a reduction of myeloma-related symptoms and side effects. The study is part of a wider project, called PREFER, examining how to represent patients in drug development. PREFER is a public-private collaborative research project under the Innovative Medicines Initiative (IMI). Continue reading

 

 

The European Commission (EC) has approved isatuximab (Sarclisa®) in combination with carfilzomib and dexamethasone (Kd) for the treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. This marks the second EC approval of isatuximab in combination with a standard of care regimen in less than 12 months. Continue reading

  

CAR-T cell therapy is a promising therapy option under investigation for the treatment of myeloma.. Different products are being studied, many with preliminary results showing high rates of response. Up until now there have been no approved CAR-T products for myeloma, however, CAR-T is now a reality after the US Food and Drug Administration (FDA) approved idecabtagene vicleucel (Abecma) as the first CAR-T cell therapy for treatment of relapsed/refractory myeloma. Continue reading

  

The European Commission (EC) has granted conditional marketing authorization for selinexor, a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) medicine, in combination with dexamethasone for the treatment of myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. Continue reading

  

Chimeric antigen receptor T cell (CAR T-cell) therapy is a form of immunotherapy that is currently being investigated in clinical trials for the treatment of myeloma. Immunotherapy works by using your immune system to fight cancer. In CAR-T-cell treatment, a type of immune cell, known as T cells, are genetically programmed with a chimeric antigen receptor (CAR) protein that enables them to recognise and destroy cancerous myeloma cells in your body. Continue reading

1 2 3 24